Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose KD2-396 booster in infants after routine DPT-IPV, Hib, and hepatitis B vaccination
jRCT2031220411Completed
- Sponsor
- KM Biologics
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of KD2-396 in pertussis, diphtheria, Tetanus and 3 more, sponsored by KM Biologics. Primary endpoints: Geometric mean fold rise for PT, FHA, diphtheria toxin, tetanus toxoid, PRP, and HBsAg, Mean difference in antibody titers against attenuated poliovirus types 1, 2, 3 and 5 more. Started Nov 2022; status: completed.
02
Drugs
KD2-396
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on jRCT2031220411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220411.